Jochen Seufert

Publication Activity (10 Years)

Years Active: 2018-2024
Publications (10 Years): 27

Top Topics

Community Dwelling

Clinical Practice

Cardiovascular Disease

Top Venues

Diabetes, obesity & metabolism

This page only lists publications with an associated author ORCID identifier.

Publications

Marie Auzanneau, Jochen Seufert, Stefan Zimny, Thomas Haak, Andrej Zeyfang, Stefan Gölz, Inge Hugenberg, Marianne Pavel, Joachim Rosenbauer, Reinhard W Holl
Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany. Diabetes, obesity & metabolism 26 (9) (2024)
Jochen Seufert, Nick Freemantle, Cristian Guja, Martin Haluzík, Mathilde Tournay, Carine Vera, Mireille Bonnemaire, Janos T Kis
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use. Diabetes, obesity & metabolism 26 (7) (2024)
Jochen Seufert, Nick Freemantle, Cristian Guja, Martin Haluzík, Mathilde Tournay, Carine Vera, Mireille Bonnemaire, Janos T Kis
Real-life effectiveness of iGlarLixi (insulin glargine 100 U/mL and lixisenatide) in people with type 2 diabetes according to prior insulin use. Diabetes, obesity & metabolism (2024)
Marie Auzanneau, Jochen Seufert, Stefan Zimny, Thomas Haak, Andrej Zeyfang, Stefan Gölz, Inge Hugenberg, Marianne Pavel, Joachim Rosenbauer, Reinhard W Holl
Regional socioeconomic deprivation associated with the use of sodium-glucose cotransporter-2 inhibitors and glucagon-like peptide-1 receptor agonists in adults with type 2 diabetes in Germany. Diabetes, obesity & metabolism (2024)
Angela Ibald-Mulli, Jochen Seufert, Julia M Hermann, Markus Laimer, Peter Bramlage, Alexandre Civet, Margot Blanchon, Simon Gosset, Alexandre Templier, W Dieter Paar, Fang Liz Zhou, Stefanie Lanzinger
Identification of Predictive Factors of Diabetic Ketoacidosis in Type 1 Diabetes Using a Subgroup Discovery Algorithm. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, John White, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: A cross-sectional survey. Diabetes, obesity & metabolism (2023)
Robert E J Ryder, Katharina Laubner, Marek Benes, Martin Haluzik, Lynne Munro, Harry Frydenberg, Julian P Teare, Aruchana Ruban, Sigal Fishman, Erwin Santo, Rainer Stengel, Charlotte De Jonge, Jan W Greve, Ricardo V Cohen, Cristina M Aboud, Gerald J Holtmann, Graeme Rich, Jess J McMaster, Tadej Battelino, Primoz Kotnik, James P Byrne, John C Mason, Justin Bessell, Jeanine Bascomb, Lillian Kow, Janes Collins, Jacob Chisholm, Peter N Pferschy, Harald Sourij, Melissa L Cull, Melanie C Wyres, Russell Drummond, Barbara McGowan, Stephanie A Amiel, Mahi Yadagiri, Piya Sen Gupta, Jens Aberle, Jochen Seufert
Endoscopic Duodenal-Jejunal Bypass Liner Treatment for Type 2 Diabetes and Obesity: Glycemic and Cardiovascular Disease Risk Factor Improvements in 1,022 Patients Treated Worldwide. Diabetes care (2023)
Tae Won Yi, Michelle M Y Wong, Brendon L Neuen, Clare Arnott, Paul Poirier, Jochen Seufert, April Slee, Wally Rapattoni, Fernando G Ang, David C Wheeler, Kenneth W Mahaffey, Vlado Perkovic, Adeera Levin
Effects of canagliflozin on cardiovascular and kidney events in patients with chronic kidney disease with and without peripheral arterial disease: integrated analysis from the CANVAS Program and CREDENCE trial. Diabetes, obesity & metabolism (2023)
Cristian Guja, János Tibor Kis, Martin Haluzík, Mireille Bonnemaire, Gregory Bigot, Mathilde Tournay, Nick Freemantle, Jochen Seufert
iGlarLixi (insulin glargine 100 U/mL plus lixisenatide) is effective and well-tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data. Diabetes, obesity & metabolism (2023)
Michael A Tsoukas, Vincent Woo, Sheldon W Tobe, April Slee, Wally Rapattoni, Fernando G Ang, Jochen Seufert, Brendon L Neuen, Clare Arnott, Kenneth W Mahaffey, David C Wheeler
Cardiovascular and kidney outcomes with canagliflozin according to type 2 diabetes treatment targets at baseline: Data from the CANVAS Program and CREDENCE. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, Maureen Carlyle, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient and physician perspectives and experiences of basal insulin titration in type 2 diabetes in the United States: Cross-sectional surveys. Diabetes, obesity & metabolism (2023)
Stewart B Harris, Kamel Mohammedi, Monica Bertolini, John White, Valery Walker, Fang Liz Zhou, John E Anderson, Jochen Seufert
Patient perspectives and experiences with basal insulin titration in type 2 diabetes in the United States: a cross-sectional survey. Diabetes, obesity & metabolism (2023)
Cristian Guja, János Tibor Kis, Martin Haluzík, Mireille Bonnemaire, Gregory Bigot, Mathilde Tournay, Nick Freemantle, Jochen Seufert
iGlarLixi (insulin glargine 100 U/ml plus lixisenatide) is effective and well tolerated in people with uncontrolled type 2 diabetes regardless of age: A REALI pooled analysis of prospective real-world data. Diabetes, obesity & metabolism (2023)
Julia M Hermann, Sascha René Tittel, Peter Bramlage, Benjamin Mayer, Andreas Fritsche, Jochen Seufert, Markus Laimer, Stefan Zimny, Sebastian M Meyhoefer, Michael Hummel, Reinhard W Holl
Disease heterogeneity of adult diabetes based on routine clinical variables at diagnosis: Results from the German/Austrian Diabetes Follow-up Registry. Diabetes, obesity & metabolism 24 (11) (2022)
Stephan Kress, Peter Bramlage, Reinhard W Holl, Christian Dominik Möller, Steffen Mühldorfer, Jörg Reindel, Jochen Seufert, Rüdiger Landgraf, Ludwig Merker, Sebastian M Meyhöfer, Thomas Danne, Peter Fasching, Peter R Mertens, Christoph Wanner, Stefanie Lanzinger
Validation of a Risk Prediction Model for Early Chronic Kidney Disease in Patients with Type 2 Diabetes: Data from the German/Austrian DPV Registry. Diabetes, obesity & metabolism (2022)
Jochen Seufert, Peter Wiesli, Andreas Fritsche, Helmut Anderten, Katrin Pegelow, Stefan Pscherer, Martin Pfohl
Switching the basal insulin to insulin glargine 300 U/ml in people with type 2 diabetes under basal insulin supported oral therapy: Observational trial on effectiveness and safety. Diabetes, obesity & metabolism 24 (1) (2021)
Susanne Tan, Stanislav Ignatenko, Frank Wagner, Anuja Dokras, Jochen Seufert, Denise Zwanziger, Karin Dunschen, Marjorie Zakaria, Neda Huseinovic, Craig T Basson, Ping Mahling, Dagmar Fuhrer, Markus Hinder
Licogliflozin versus placebo in women with polycystic ovary syndrome: A randomized, double-blind, phase 2 trial. Diabetes, obesity & metabolism 23 (11) (2021)
Jochen Seufert, Stefanie Lanzinger, Thomas Danne, Peter Bramlage, Sebastian M Schmid, Florian Kopp, Stephan Kress, Peter Fasching, Claus Schäfer, Reinhard W Holl, null null
Real-world data of 12-month adjunct sodium-glucose co-transporter-2 inhibitor treatment in type 1 diabetes from the German/Austrian DPV registry: Improved HbA1c without diabetic ketoacidosis. Diabetes, obesity & metabolism 24 (4) (2021)
Svenja Meyhöfer, Alexander J Eckert, Michael Hummel, Markus Laimer, Michael Roden, Stephan Kress, Jochen Seufert, Sebastian M Meyhöfer, Reinhard W Holl
Elevated liver enzymes and comorbidities in type 2 diabetes: Multicenter analysis of 51,645 patients of the DPV database. Diabetes, obesity & metabolism (2021)
Emma G Wilmot, Kelly L Close, Dubravka Jurišić-Eržen, Daniela Bruttomesso, Francisco Javier Ampudia-Blasco, Zsolt Bosnyak, Aude Roborel de Climens, Grégory Bigot, Anne L Peters, Eric Renard, Lori D Berard, Luis Eduardo Calliari, Jochen Seufert
Patient-reported outcomes in adults with type 1 diabetes in global real-world clinical practice: The SAGE study. Diabetes, obesity & metabolism 23 (8) (2021)
Martin Pfohl, François R Jornayvaz, Andreas Fritsche, Stefan Pscherer, Helmut Anderten, Katrin Pegelow, Jochen Seufert
Effectiveness and safety of insulin glargine 300 U/mL in insulin-naïve patients with type 2 diabetes after failure of oral therapy in a real-world setting. Diabetes, obesity & metabolism 22 (5) (2020)
Hannes Kalscheuer, Jochen Seufert, Stefanie Lanzinger, Joachim Rosenbauer, Wolfram Karges, Dominik Bergis, Julia Katharina Mader, Stefan Zimny, Sebastian M Schmid, Michael Hummel, Wolfgang Kerner, Reinhard W Holl, null null
Event Rates and Risk Factors for the Development of Diabetic Ketoacidosis in Adult Patients With Type 1 Diabetes: Analysis From the DPV Registry Based on 46,966 Patients. Diabetes care 42 (3) (2019)
Martin Pfohl, Stefan Pscherer, Andreas Fritsche, Helmut Anderten, Anja Borck, Katrin Pegelow, Peter Bramlage, Jochen Seufert
Predictors of treatment response in type-2 diabetes patients initiating basal-supported oral therapy with insulin glargine 100 U/mL: A sub-analysis of the Titration and OPtimisation (TOP) registry. Diabetes, obesity & metabolism 21 (9) (2019)
Alice Y Y Cheng, Stewart Harris, Francesco Giorgino, Jochen Seufert, Robert Ritzel, Kamlesh Khunti F MedSci, Felipe Lauand, Lydie Melas-Melt, Jukka Westerbacka, Zsolt Bosnyak, Julio Rosenstock
Similar glycaemic control and less hypoglycaemia during active titration after insulin initiation with glargine 300 units/mL and degludec 100 units/mL: A subanalysis of the BRIGHT study. Diabetes, obesity & metabolism 22 (3) (2019)
Jochen Seufert, Andreas Fritsche, Stefan Pscherer, Helmut Anderten, Anja Borck, Katrin Pegelow, Peter Bramlage, Martin Pfohl
Titration and optimization trial for the initiation of insulin glargine 100 U/mL in patients with inadequately controlled type 2 diabetes on oral antidiabetic drugs. Diabetes, obesity & metabolism 21 (2) (2018)
Katharina Laubner, Nina Riedel, Katharina Fink, Reinhard W Holl, Reinhard Welp, Hans-Peter Kempe, Anne Lautenbach, Matthias Schlensak, Rainer Stengel, Thomas Eberl, Frank Dederichs, Henning Schwacha, Jochen Seufert, Jens Aberle
Comparative efficacy and safety of the duodenal-jejunal bypass liner in obese patients with type 2 diabetes mellitus: A case control study. Diabetes, obesity & metabolism 20 (8) (2018)
Dirk Müller-Wieland, Monika Kellerer, Katarzyna Cypryk, Dasa Skripova, Katja Rohwedder, Eva Johnsson, Ricardo Garcia-Sanchez, Raisa Kurlyandskaya, C David Sjöström, Stephan Jacob, Jochen Seufert, Nalina Dronamraju, Katalin Csomós
Efficacy and safety of dapagliflozin or dapagliflozin plus saxagliptin versus glimepiride as add-on to metformin in patients with type 2 diabetes. Diabetes, obesity & metabolism 20 (11) (2018)